Silver Book Fact

Deep Brain Stimulation for Parkinson’s Adds QALYs and Saves Money

Fact image

Pietzsch J, Garner A, Marks W. Cost Effectiveness of Deep Brain Stimulation for Advanced Parkinson’s Disease in the United States. Neuromodulation. 2016; 19(7). https://onlinelibrary.wiley.com/doi/abs/10.1111/ner.12474

Reference

Title
Cost Effectiveness of Deep Brain Stimulation for Advanced Parkinson’s Disease in the United States
Publication
Neuromodulation
Publication Date
2016
Authors
Pietzsch J, Garner A, Marks W
Volume & Issue
Volume 19, Issue 7
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value
  • Economic Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, because of medical research, the number of Americans with Alzheimer’s could decrease by 3 million in 2025.  
  • Out-of-Pocket Costs, 5-Year Delayed Onset  
  • 2006 Medicines in Development for Neurologic Disorders  
  • Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.  
  • Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.